Abstract
Lung cancer is the leading cause of cancer deaths associated with poor prognosis. Patients with advanced lung cancer had been “uniformly” treated with platinum-based cytotoxic chemotherapy, which had provided an only modest clinical benefit. However, recent advances in molecular diagnosis and systemic treatment targeting cancer hallmarks such as angiogenesis, oncogenic gene alteration, and evasion from cancer immunity have dramatically changed treatment strategies associated with a tremendous improvement in outcomes of lung cancer patients. Here, we review current status and future perspectives of molecular diagnosis and personalized “precision” medicine for lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
